74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Elekta AB
Open
54.3 -3.12
Overview
Share price change
24h
Min
53.5
Max
56.05
Income | -220M 10M |
|---|---|
Sales | 169M 4.2B |
P/E Sector Avg | 74.079 57.833 |
EPS | 0.88 |
Dividend yield | 4.28 |
Profit margin | 0.236 |
Employees | 4,438 |
EBITDA | 111M 640M |
Dividend yield Sector Avg | 4.28% 2.47% |
|---|---|
Next Earnings | 28 May 2026 |
Market Cap | 12M 22B |
|---|---|
Previous open | 57.42 |
Previous close | 54.3 |
Elekta AB Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Elekta AB Forecast
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Elekta AB
Elekta AB (publ), a medical technology company, engages in the provision of clinical solutions for treating cancer and brain disorders worldwide. The company offers radiation therapy products, including Elekta Unity for real-time MR visualization; Elekta Versa HD, a brain metastases solution; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; and quality assurance, and treatment and motion management solutions. It also provides stereotactic radiosurgery products, such as Elekta Esprit; Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for radiosurgeons; and Leksell GammaPlan, a treatment planning and management software. In addition, the company offers Elekta ONE, a software suite of multiple Elekta solutions. Further, it provides brachytherapy products, including Elekta Studio, an image guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Elekta Xoft Axxent, and electronic brachytherapy systems; Elekta Geneva, an applicator for cervical cancer patients; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Venezia applicator that enables the oncologist to treat locally advanced cervical cancer. Additionally, the company offers neurosurgery products, such as Leksell Vantage Stereotactic System for intracranial neurosurgery. Furthermore, it provides Elekta Kaiku for personalized cancer care; and veterinary radiation therapy solutions. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
Other stocks from the sector
Live chat